Decreased beta-cell mass in diabetes: Significance, mechanisms and therapeutic implications

Diabetologia

Volumn 47, Issue 3, 2004, Pages 581-589

  Donath, M Y ^a   Halban, P A ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Apoptosis; Cytokines; Hyperglycaemia; Insulin; Proliferation

Indexed keywords

GLIBENCLAMIDE; INSULIN;

APOPTOSIS; AUTOIMMUNITY; CELL DEATH; CELL FUNCTION; CELL PROLIFERATION; CELL SECRETION; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW;

CELL DEATH; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; ISLETS OF LANGERHANS;

EID: 1842844414     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-004-1336-4     Document Type: Review

References (87)

1. Yalow RS, Berson SA (1960) Plasma insulin concentrations in nondiabetic and early diabetic subjects: determinations by a new sensitive immuno-assay technic. Diabetes 9:254-260
2. Karam JH, Grodsky G, Forsham PH (1963) Excessive insulin response to glucose in obese subjects as measured by immunochemical assay. Diabetes 12:197-204
3. Cerasi E, Luft R (1967) Insulin response to glucose infusion in diabetic and non-diabetic monozygotic twin pairs. Genetic control of insulin response? Acta Endocrinol (Copenh) 55:330-345
4. DeFronzo RA (1988) Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667-687
5. Maclean N, Ogilvie RF (1955) Quantitative estimation of the pancreatic islet tissue in diabetic subjects. Diabetes 4:367-376
6. Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU (1985) Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 4:110-125
7. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S (2002) Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 45:85-96
8. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with Type 2 diabetes. Diabetes 52: 102-110
9. Yoon KH, Ko SH, Cho JH et al. (2003) Selective beta-cell loss and alpha-cell expansion in patients with Type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 88:2300-2308
10. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D (1987) Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 30:698-702
11. Kahn SE, Halban PA (1997) Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 46:1725-1732
12. Ward WK, Beard JC, Halter JB, Pfeifer MA, Porte D, Jr. (1984) Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes Care 7:491-502
13. Porksen N (2002) Early changes in beta-cell function and insulin pulsatility as predictors for type 2 diabetes. Diabetes Nutr Metab 15:9-14
14. Polonsky KS, Given BD, Hirsch LJ et al. (1988) Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 318:1231-1239
15. Kahn SE (2003) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46:3-19
16. Porksen N (2002) The in vivo regulation of pulsatile insulin secretion. Diabetologia 45:3-20
17. Ward GM, Walters JM, Aitken PM, Best JD, Alford FP (1990) Effects of prolonged pulsatile hyperinsulinemia in humans. Enhancement of insulin sensitivity. Diabetes 39: 501-507
18. Hellerstrom C (1984) The life story of the pancreatic B cell. Diabetologia 26:393-400
19. Bonner-Weir S (2000) Islet growth and development in the adult. J Mol Endocrinol 24:297-302
20. Verchere CB, D Alessio DA, Palmiter RD et al. (1996) Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:3492-3496
21. Kahn SE, Andrikopoulos S, Verchere CB (1999) Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48:241-253
22. Janson J, Soeller WC, Roche PC et al. (1996) Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:7283-7288
23. Westermark P (1996) Islet pathology of non-insulin-dependent diabetes mellitus (NIDDM). Diabet Med 13:S46-S48
24. Eizirik DL, Mandrup-Poulsen T (2001) A choice of death - the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 44:2115-2133
25. Corbett J, Serup P, Bonner Weir S, Nielsen JH (1997) Beta-cell ontogeny: growth and death. Diabetologia 40 [Suppl 3]:B27-B32
26. Donath MY, Storling J, Maedler K, Mandrup-Poulsen T (2003) Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med 81: 455-470
27. Federici M, Hribal M, Perego L et al. (2001) High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes 50:1290-1301
28. Maedler K, Spinas GA, Lehmann R et al. (2001) Glucose induces beta-cell apoptosis via upregulation of the fas receptor in human islets. Diabetes 50:1683-1690
29. 2+ concentration. JBC 273:33501-33507
30. Hoorens A, Van de Casteele M, Kloppel G, Pipeleers D (1996) Glucose promotes survival of rat pancreatic beta cells by activating synthesis of proteins which suppress a constitutive apoptotic program. JCI 98:1568-1574
31. Donath MY, Gross DJ, Cerasi E, Kaiser N (1999) Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes 48:738-744
32. Chick WL, Like AA (1970) Studies in the diabetic mutant mouse. 3. Physiological factors associated with alterations in beta cell proliferation. Diabetologia 6:243-251
33. Lipsett M, Finegood DT (2002) Beta-cell neogenesis during prolonged hyperglycemia in rats. Diabetes 51:1834-1841
34. Paris M, Bernard-Kargar C, Berthault MF, Bouwens L, Ktorza A (2003) Specific and combined effects of insulin and glucose on functional pancreatic beta-cell mass in vivo in adult rats. Endocrinology 144:2717-2727
35. Harding HP, Ron D (2002) Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes 51: S455-S461
36. Araki E, Oyadomari S, Mori M (2003) Endoplasmic reticulum stress and diabetes mellitus. Intern Med 42:7-14
37. Izumi T, Yokota-Hashimoto H, Zhao S, Wang J, Halban PA, Takeuchi T (2003) Dominant negative pathogenesis by mutant proinsulin in the akita diabetic mouse. Diabetes 52: 409-416
38. Halban PA, Kahn SE, Lernmark A, Rhodes CJ (2001) Gene and cell-replacement therapy in the treatment of type 1 diabetes: how high must the standards be set? Diabetes 50: 2181-2191
39. Grill V, Bjorklund A (2001) Overstimulation and beta-cell function. Diabetes 50 [Suppl 1]:S122-124
40. Ihara Y, Toyokuni S, Uchida K et al. (1999) Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. Diabetes 48:927-932
41. Laybutt DR, Kaneto H, Hasenkamp W et al. (2002) Increased expression of antioxidant and antiapoptotic genes in islets that may contribute to [beta]-cell survival during chronic hyperglycemia. Diabetes 51:413-423
42. Maedler K, Sergeev P, Ris F et al. (2002) Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. JCI 110:851-860
43. Maedler K, Fontana A, Ris F et al. (2002) FLIP switches Fas-mediated glucose signaling in human pancreatic beta cells from apoptosis to cell replication. Proc Natl Acad Sci USA 99:8236-8241
44. Shimabukuro M, Zhou YT, Levi M, Unger RH (1998) Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 95:2498-2502
45. Roehrich ME, Mooser V, Lenain V et al. (2003) Insulin-secreting beta-cell dysfunction induced by human lipoproteins. JBC 278:18368-18375
46. Maedler K, Spinas GA, Dyntar D, Moritz W, Kaiser N, Donath MY (2001) Distinct effects of saturated and monounsaturated fatty acids on beta-cell turnover and function. Diabetes 50:69-76
47. Unger RH, Orci L (2002) Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta 1585:202-212
48. Poitout V, Robertson RP (2002) Minireview: Secondary beta-Cell Failure in Type 2 Diabetes-A Convergence of Glucotoxicity and Lipotoxicity. Endocrinology 143:339-342
49. El-Assaad W, Buteau J, Peyot ML et al. (2003) Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology 144:4154-4163
50. Roduit R, Thorens B (1997) Inhibition of glucose-induced insulin secretion by long-term preexposure of pancreatic islets to leptin. FEBS Lett 415:179-182
51. Kieffer TJ, Habener JF (2000) The adipoinsular axis: effects of leptin on pancreatic beta-cells. Am J Physiol Endocrinol Metab 278:E1-E14
52. Shimabukuro M, Wang MY, Zhou YT, Newgard CB, Unger RH (1998) Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2 expression. Proc Natl Acad Sci USA 95:9558-9561
53. Kendall DM, Sutherland DE, Najarian JS, Goetz FC, Robertson RP (1990) Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans. N Engl J Med 322:898-903
54. Bonner-Weir S, Trent DF, Weir GC (1983) Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J Clin Invest 71:1544-1553
55. Weir GC, Leahy JL, Bonner-Weir S (1986) Experimental reduction of B-cell mass: implications for the pathogenesis of diabetes. Diabetes Metab Rev 2:125-161
56. Kjems LL, Kirby BM, Welsh EM et al. (2001) Decrease in beta-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig. Diabetes 50:2001-2012
57. Kaiser N, Corcos AP, Sarel I, Cerasi E (1991) Monolayer culture of adult rat pancreatic islets on extracellular matrix: modulation of B-cell function by chronic exposure to high glucose. Endocrinology 129:2067-2076
58. Eizirik DL, Korbutt GS, Hellerstrom C (1992) Prolonged exposure of human pancreatic islets to high glucose concentrations in vitro impairs the beta-cell function. J Clin Invest 90:1263-1268
59. Leahy JL, Cooper HE, Deal DA, Weir GC (1986) Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. A study in normal rats using chronic in vivo glucose infusions. J Clin Invest 77:908-915
60. UK Prospective Diabetes Study Group (1995) UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258
61. Leahy JL, Bonner-Weir S, Weir BC (1988) Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy. J Clin Invest 81:1407-1414
62. Kahn SE, Bergman RN, Schwartz MW, Taborsky GJ Jr, Porte D Jr (1992) Short-term hyperglycemia and hyperinsulinemia improve insulin action but do not alter glucose action in normal humans. Am J Physiol 262:E518-523
63. Glaser B, Cerasi E (1999) Early intensive insulin treatment for induction of long-term glycaemic control in type 2 diabetes. Diabetes Obes Metab 1:67-74
64. Polyzogopoulou EV, Kalfarentzos F, Vagenakis AG, Alexandrides TK (2003) Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes 52:1098-1103
65. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ (2003) Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. JBC 278:471-478
66. Drucker DJ (2003) Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 17:161-171
67. Greenwood RH, Mahler RF, Hales CN (1976) Improvement in insulin secretion in diabetes after diazoxide. Lancet 1:444-447
68. Bjork E, Berne C, Karlsson FA (1998) Induction of beta-cell rest in type 1 diabetes. Studies on the effects of octreotide and diazoxide. Diabetes Care 21:427-430
69. Guldstrand M, Grill V, Bjorklund A, Lins PE, Adamson U (2002) Improved beta cell function after short-term treatment with diazoxide in obese subjects with type 2 diabetes. Diabetes Metab 28:448-456
70. Report of the expert committee on the diagnosis and classification of diabetes mellitus (2003) Diabetes Care 26 [Suppl 1]:S5-S20
71. Pietropaolo M, Barinas-Mitchell E, Pietropaolo SL, Kuller LH, Trucco M (2000) Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes. Diabetes 49:32-38
72. Hypponen E, Virtanen SM, Kenward MG, Knip M, Akerblom HK (2000) Obesity, increased linear growth, and risk of type 1 diabetes in children. Diabetes Care 23:1755-1760
73. Kibirige M, Metcalf B, Renuka R, Wilkin TJ (2003) Testing the accelerator hypothesis: the relationship between body mass and age at diagnosis of type 1 diabetes. Diabetes Care 26:2865-2870
74. Libman IM, Pietropaolo M, Arslanian SA, LaPorte RE, Becker DJ (2003) Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes. Diabetes Care 26:2871-2875
75. Syed MA, Barinas-Mitchell E, Pietropaolo SL et al. (2002) Is type 2 diabetes a chronic inflammatory/autoimmune disease? Diabetes Nutr Metab 15:68-83.
76. Pickup JC, Crook MA (1998) Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41: 1241-1248
77. Spranger J, Kroke A, Mohlig M et al. (2003) Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52:812-817
78. Bellone M, Iezzi G, Rovere P et al. (1997) Processing of engulfed apoptotic bodies yields T cell epitopes. J Immunol 159:5391-5399
79. O'Brien BA, Harmon BV, Cameron DP, Allan DJ (1997) Apoptosis is the mode of beta-cell death responsible for the development of IDDM in the nonobese diabetic (NOD) mouse. Diabetes 46:750-757
80. Johnson JD, Ahmed NT, Luciani DS et al. (2003) Increased islet apoptosis in Pdx1(+/-) mice. JCI 111:1147-1160
81. Wilkin TJ (2001) The accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes. Diabetologia 44:914-922
82. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Diabetes Care 20:1183-1197
83. Diabetes Prevention Program (DPP) Research Group (2002) The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 25:2165-2171
84. Tuomilehto J, Lindstrom J, Eriksson JG et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350
85. Pan XR, Li GW, Hu YH et al. (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544
86. Maedler K, Bucher P, Berney T, Spinas GA, Carr RD, Donath MY (2003) Differential effects of repaglinide, nateglinide and glibenclamide on apoptosis in human beta cells in vitro. Diabetologia 46 [Suppl 2]:A187 (Abstract)
87. Alvarsson M, Sundkvist G, Lager I et al. (2003) Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 26:2231-2237